Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Skyrizi® (risankizumab-rzaa) – New indication
June 18, 2024 - AbbVie announced the FDA approval of Skyrizi (risankizumab-rzaa), for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
